539 related articles for article (PubMed ID: 16151415)
1. Influence of a selective histamine H3 receptor antagonist on hypothalamic neural activity, food intake and body weight.
Malmlöf K; Zaragoza F; Golozoubova V; Refsgaard HH; Cremers T; Raun K; Wulff BS; Johansen PB; Westerink B; Rimvall K
Int J Obes (Lond); 2005 Dec; 29(12):1402-12. PubMed ID: 16151415
[TBL] [Abstract][Full Text] [Related]
2. Increase of neuronal histamine in obese rats is associated with decreases in body weight and plasma triglycerides.
Malmlöf K; Golozoubova V; Peschke B; Wulff BS; Refsgaard HH; Johansen PB; Cremers T; Rimvall K
Obesity (Silver Spring); 2006 Dec; 14(12):2154-62. PubMed ID: 17189541
[TBL] [Abstract][Full Text] [Related]
3. Evidence for tolerance following repeated dosing in rats with ciproxifan, but not with A-304121.
Pan JB; Yao BB; Miller TR; Kroeger PE; Bennani YL; Komater VA; Esbenshade TA; Hancock AA; Decker MW; Fox GB
Life Sci; 2006 Aug; 79(14):1366-79. PubMed ID: 16730751
[TBL] [Abstract][Full Text] [Related]
4. Antagonistic targeting of the histamine H3 receptor decreases caloric intake in higher mammalian species.
Malmlöf K; Hastrup S; Wulff BS; Hansen BC; Peschke B; Jeppesen CB; Hohlweg R; Rimvall K
Biochem Pharmacol; 2007 Apr; 73(8):1237-42. PubMed ID: 17328868
[TBL] [Abstract][Full Text] [Related]
5. Effects of a selective melanin-concentrating hormone 1 receptor antagonist on food intake and energy homeostasis in diet-induced obese mice.
Kowalski TJ; Spar BD; Weig B; Farley C; Cook J; Ghibaudi L; Fried S; O'Neill K; Del Vecchio RA; McBriar M; Guzik H; Clader J; Hawes BE; Hwa J
Eur J Pharmacol; 2006 Mar; 535(1-3):182-91. PubMed ID: 16540104
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
Esbenshade TA; Fox GB; Krueger KM; Baranowski JL; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan JB; Faghih R; Bennani YL; Williams M; Hancock AA
Biochem Pharmacol; 2004 Sep; 68(5):933-45. PubMed ID: 15294456
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist.
Antal-Zimanyi I; Bruce MA; Leboulluec KL; Iben LG; Mattson GK; McGovern RT; Hogan JB; Leahy CL; Flowers SC; Stanley JA; Ortiz AA; Poindexter GS
Eur J Pharmacol; 2008 Aug; 590(1-3):224-32. PubMed ID: 18573246
[TBL] [Abstract][Full Text] [Related]
8. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures.
Mack CM; Moore CX; Jodka CM; Bhavsar S; Wilson JK; Hoyt JA; Roan JL; Vu C; Laugero KD; Parkes DG; Young AA
Int J Obes (Lond); 2006 Sep; 30(9):1332-40. PubMed ID: 16534527
[TBL] [Abstract][Full Text] [Related]
9. Chronic intracerebroventricular administration of recombinant CART(42-89) peptide inhibits and causes weight loss in lean and obese Zucker (fa/fa) rats.
Larsen PJ; Vrang N; Petersen PC; Kristensen P
Obes Res; 2000 Nov; 8(8):590-6. PubMed ID: 11156435
[TBL] [Abstract][Full Text] [Related]
10. Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor.
Criscione L; Rigollier P; Batzl-Hartmann C; Rüeger H; Stricker-Krongrad A; Wyss P; Brunner L; Whitebread S; Yamaguchi Y; Gerald C; Heurich RO; Walker MW; Chiesi M; Schilling W; Hofbauer KG; Levens N
J Clin Invest; 1998 Dec; 102(12):2136-45. PubMed ID: 9854049
[TBL] [Abstract][Full Text] [Related]
11. Effect of chronic m-CPP on locomotion, hypophagia, plasma corticosterone and 5-HT2C receptor levels in the rat.
Fone KC; Austin RH; Topham IA; Kennett GA; Punhani T
Br J Pharmacol; 1998 Apr; 123(8):1707-15. PubMed ID: 9605579
[TBL] [Abstract][Full Text] [Related]
12. Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist.
Hancock AA; Bennani YL; Bush EN; Esbenshade TA; Faghih R; Fox GB; Jacobson P; Knourek-Segel V; Krueger KM; Nuss ME; Pan JB; Shapiro R; Witte DG; Yao BB
Eur J Pharmacol; 2004 Mar; 487(1-3):183-97. PubMed ID: 15033391
[TBL] [Abstract][Full Text] [Related]
13. Sch 50971, an orally active histamine H3 receptor agonist, inhibits central neurogenic vascular inflammation and produces sedation in the guinea pig.
McLeod RL; Aslanian R; del Prado M; Duffy R; Egan RW; Kreutner W; McQuade R; Hey JA
J Pharmacol Exp Ther; 1998 Oct; 287(1):43-50. PubMed ID: 9765320
[TBL] [Abstract][Full Text] [Related]
14. Development of chiral N-alkylcarbamates as new leads for potent and selective H3-receptor antagonists: synthesis, capillary electrophoresis, and in vitro and oral in vivo activity.
Sasse A; Kiec-Kononowicz K; Stark H; Motyl M; Reidemeister S; Ganellin CR; Ligneau X; Schwartz JC; Schunack W
J Med Chem; 1999 Feb; 42(4):593-600. PubMed ID: 10052966
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687).
McLeod RL; Rizzo CA; West RE; Aslanian R; McCormick K; Bryant M; Hsieh Y; Korfmacher W; Mingo GG; Varty L; Williams SM; Shih NY; Egan RW; Hey JA
J Pharmacol Exp Ther; 2003 Jun; 305(3):1037-44. PubMed ID: 12649305
[TBL] [Abstract][Full Text] [Related]
16. Effect of a selective OX1R antagonist on food intake and body weight in two strains of rats that differ in susceptibility to dietary-induced obesity.
White CL; Ishii Y; Mendoza T; Upton N; Stasi LP; Bray GA; York DA
Peptides; 2005 Nov; 26(11):2331-8. PubMed ID: 15893404
[TBL] [Abstract][Full Text] [Related]
17. Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist.
Ligneau X; Lin J; Vanni-Mercier G; Jouvet M; Muir JL; Ganellin CR; Stark H; Elz S; Schunack W; Schwartz J
J Pharmacol Exp Ther; 1998 Nov; 287(2):658-66. PubMed ID: 9808693
[TBL] [Abstract][Full Text] [Related]
18. The histamine H3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA-induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons.
Dai H; Fu Q; Shen Y; Hu W; Zhang Z; Timmerman H; Leurs R; Chen Z
Eur J Pharmacol; 2007 Jun; 563(1-3):117-23. PubMed ID: 17350613
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effect of an H(3)-inverse agonist on energy intake and hypothalamic histamine release in normal mice and leptin resistant mice with high fat diet-induced obesity.
Ishizuka T; Hatano K; Murotani T; Yamatodani A
Behav Brain Res; 2008 Apr; 188(2):250-4. PubMed ID: 18082276
[TBL] [Abstract][Full Text] [Related]
20. G protein-dependent pharmacology of histamine H3 receptor ligands: evidence for heterogeneous active state receptor conformations.
Krueger KM; Witte DG; Ireland-Denny L; Miller TR; Baranowski JL; Buckner S; Milicic I; Esbenshade TA; Hancock AA
J Pharmacol Exp Ther; 2005 Jul; 314(1):271-81. PubMed ID: 15821027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
